Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Childhood Cancer
93%
Pediatric Acute Myeloid Leukemia
68%
Acute Lymphoblastic Leukemia
56%
Pediatrics
56%
Chemotherapy
54%
Pontine Glioma
41%
Malignant Neoplasm
36%
Overall Survival
33%
Diseases
28%
Event Free Survival
26%
Treatment Outcome
21%
Adolescence
20%
Acute Myelogenous Leukemia
20%
Cancer Therapy
18%
Pediatrics Patient
17%
Minimal Residual Disease
16%
Tumor
16%
Supportive Care
15%
Survival Rate
15%
Leukemia
15%
Oncology
15%
Low and Middle Income Countries
14%
Radiation Therapy
13%
Cytarabine
13%
High Risk Population
13%
Clinical Trial
12%
Vincristine
12%
Ganglioneuroblastoma
12%
Ganglioglioma
11%
Retrospective Study
11%
Cancer
11%
Quality of Life
11%
Cohort Analysis
10%
Cancer-Related Fatigue
10%
Randomized Controlled Trial
9%
Doxorubicin
9%
Neoplasm
9%
Injection
9%
Health Care Personnel
8%
Cumulative Incidence
8%
Childhood Leukemia
8%
Prognostic Factor
8%
Ovarian Reserve
8%
Patient Referral
8%
Drug Resistance
8%
Hazard Ratio
8%
Infusion
8%
Reproductive Medicine
8%
Treatment Response
8%
Keyphrases
Acute Myeloid Leukemia
94%
Pediatric Leukemia
67%
Childhood Acute Lymphoblastic Leukemia
60%
Diffuse Intrinsic Pontine Glioma
51%
Acute Lymphoblastic Leukemia
44%
Dutch
33%
Pediatric
32%
Children with Cancer
32%
Childhood Cancer
24%
Drug Resistance
23%
Overall Survival
22%
Kenya
19%
Pediatric Acute Lymphoblastic Leukemia
19%
Pediatric Patients
18%
Vincristine-induced Peripheral Neuropathy
18%
Cytarabine
17%
Event-free Survival
16%
Quality of Life
16%
Chemotherapy
16%
Pediatric Oncology
15%
Leukemia Patients
15%
Netherlands
15%
Methotrexate
15%
Health-related Quality of Life
15%
Randomized Controlled Trial
15%
Cellular Drugs
15%
L-asparaginase
15%
Newly Diagnosed
15%
Prednisolone
15%
Relapsed Acute Myeloid Leukemia
14%
Late Effects
14%
Leukemia
13%
Childhood Cancer Patients
13%
Oncology
13%
Radiotherapy
13%
Childhood Cancer Treatment
12%
Prognostic Significance
12%
Childhood Leukemia
12%
Low-middle Income Countries
12%
Supportive Care
12%
High Risk
11%
Tumor
11%
Deoxycytidine Kinase
11%
Treatment Outcome
11%
Survivors
11%
Daunorubicin
11%
Pediatric Cancer Patients
11%
Healthcare Providers
10%
Women Survivors
10%
Working Diagnosis
10%
